Works matching IS 22351795 AND DT 2022 AND VI 11 AND IP 6
Results: 14
Contents Vol. 11, 2022.
- Published in:
- Liver Cancer (2235-1795), 2022, v. 11, n. 6, p. I, doi. 10.1159/000528106
- Publication type:
- Article
Front & Back Matter.
- Published in:
- Liver Cancer (2235-1795), 2022, v. 11, n. 6, p. 1, doi. 10.1159/000528495
- Publication type:
- Article
APPLE News.
- Published in:
- Liver Cancer (2235-1795), 2022, v. 11, n. 6, p. 582, doi. 10.1159/000528105
- Publication type:
- Article
Acknowledgement to Reviewers.
- Published in:
- Liver Cancer (2235-1795), 2022, v. 11, n. 6, p. 583, doi. 10.1159/000527592
- Publication type:
- Article
Implications of the TACTICS Trial: Establishing the New Concept of Combination/Sequential Systemic Therapy and Transarterial Chemoembolization to Achieve Synergistic Effects.
- Published in:
- Liver Cancer (2235-1795), 2022, v. 11, n. 6, p. 487, doi. 10.1159/000527404
- By:
- Publication type:
- Article
Immune Checkpoint Inhibitor-Related Pneumonia in Unresectable Hepatocellular Carcinoma: Two Fatal Cases under Atezolizumab plus Bevacizumab.
- Published in:
- Liver Cancer (2235-1795), 2022, v. 11, n. 6, p. 572, doi. 10.1159/000526388
- By:
- Publication type:
- Article
Chinese Expert Consensus on Immunotherapy for Hepatocellular Carcinoma (2021 Edition).
- Published in:
- Liver Cancer (2235-1795), 2022, v. 11, n. 6, p. 511, doi. 10.1159/000526038
- By:
- Publication type:
- Article
Response to the Article on Antibiotics and Immune Checkpoint Inhibitors by Lin et al.
- Published in:
- Liver Cancer (2235-1795), 2022, v. 11, n. 6, p. 578, doi. 10.1159/000526003
- By:
- Publication type:
- Article
Erratum.
- Published in:
- 2022
- Publication type:
- Correction Notice
Atezolizumab plus Bevacizumab versus Sorafenib for Unresectable Hepatocellular Carcinoma: Results from Older Adults Enrolled in the IMbrave150 Randomized Clinical Trial.
- Published in:
- Liver Cancer (2235-1795), 2022, v. 11, n. 6, p. 558, doi. 10.1159/000525671
- By:
- Publication type:
- Article
Hepatitis B Virus Treatment and Hepatocellular Carcinoma: Controversies and Approaches to Consensus.
- Published in:
- Liver Cancer (2235-1795), 2022, v. 11, n. 6, p. 497, doi. 10.1159/000525518
- By:
- Publication type:
- Article
Sulfatase-2 from Cancer Associated Fibroblasts: An Environmental Target for Hepatocellular Carcinoma?
- Published in:
- Liver Cancer (2235-1795), 2022, v. 11, n. 6, p. 540, doi. 10.1159/000525375
- By:
- Publication type:
- Article
Real Life Study of Lenvatinib Therapy for Hepatocellular Carcinoma: RELEVANT Study.
- Published in:
- Liver Cancer (2235-1795), 2022, v. 11, n. 6, p. 527, doi. 10.1159/000525145
- By:
- Publication type:
- Article
Impact of Antibiotics Use on Cancer-Related and All-Cause Mortality among Patients Receiving Immunotherapy for Advanced Hepatocellular Carcinoma.
- Published in:
- Liver Cancer (2235-1795), 2022, v. 11, n. 6, p. 576, doi. 10.1159/000525028
- By:
- Publication type:
- Article